Skip to content

Reporting names would be a deterrent to HIV testing, Californian study shows

Barriers to ART scale up, and potential solutions

TMC114 expanded access programme announced: regulatory approval to be sought early next year

Tenofovir may linger up to 3 weeks in body: discontinue with caution

Meta-analysis highlights wide variation in success of developing world HIV treatment

Traditional healers being integrated into HIV care and treatment in Kwazulu-Natal

Response to HAART improves due to better drugs and more expertise in their use

Rifampicin resistance linked to dosing schedule in HIV-positive TB patients

PEPFAR working closely with South African government to support HIV treatment and care